We further described an RBCEV surface functionalization method with EGFR‐targeted nanobodies, which can enhance the delivery of RIG‐I agonists toward EGFR‐positive cancer cells, thereby improving therapeutic efficacy while reducing side effects. This evidence concerns the gene EGFR and cancer.